Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB Pharmaceuticals publishes long-term efficacy data for Neupro

UCB Pharmaceuticals publishes long-term efficacy data for Neupro

14th April 2010

UCB Pharmaceuticals has presented data from a long-term clinical study demonstrating the effectiveness of Neupro, its treatment for restless legs syndrome (RLS).

According to results showcased at the American Academy of Neurology annual meeting, patients trialled over five years using UCB’s rotigotine treatment experienced sustained improvements in symptoms.

The trial was conducted among 295 patients with moderate to severe RLS, more than a third of whom were able to remain symptom-free over the course of the five-year study period.

Dr Diego Garcia-Borreguero, director of the Sleep Research Institute in Madrid, said these findings could prove vital for sufferers of the condition, who often spend long periods of time attempting to find a diagnosis or treatment.

He said: “These five-year results provide additional evidence that once they start using rotigotine, people with RLS may experience long term relief from their symptoms.”

Last month, the company announced that Alexandre Van Damme and Bert De Graeve have been selected as potential candidates to join its board of directors, with Prince Lorenz of Belgium to step down from the board later this month.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.